Psoriatic arthritis patients with moderate disease activity were more likely to reach treatment targets or low disease activity at week 52 with apremilast (Otezla, Celgene) than patients with high disease activity, researchers report in the January 7 issue of Arthritis Care and Research.
Rheumatology Network Editorial Staff
Patients and doctors still haven't fully invested in the use of biosimilars, despite a steady rise in the cost of biologics, shows a new report by Harvard researchers.
Updated treatment guidelines for hand, hip and knee osteoarthritis have been issued. In this slideshow, we highlight recommendations for the use (or not) of drug and nondrug treatments. These include strong recommendations for standard treatment options, such as weight loss and Tai Chi, and strong recommendations against treatments with pharmacologicals, such as glucosamine and chondroitin sulfate (except for hand osteoarthritis). Learn more in this slideshow.
The American College of Rheumatology (ACR), in partnership with the Arthritis Foundation, has issued treatment guidelines for osteoarthritis of the hand, hip and knee. This is the first update since 2012.
In a review published last month in Autoimmunity Reviews, British researchers outline factors physicians should consider when contemplating tapering biologic therapies in patients with inflammatory arthritis. How best to wean patients from biologic therapy is an issue that comes up more frequently these days as patients increasingly achieve remission or low disease activity. In this slideshow, we highlight considerations physicians may want to consider in treating these patients.
A 62-year-old woman complained to her doctor about joint pain in her fingers. The joints in her fingers were warm, tender, and slightly swollen. Can you diagnose this patient?
In this slideshow, we feature the lupus stories that resonated most with our readers in 2019: Lupus patients are increasingly turning to opioid use to control pain, a study that shows anifrolumab may be the next belimumab for lupus, patients are turning to pill splitting to keep costs down, among others.
In this slideshow, we revisit some of our most popular stories of the year: Insurers weigh in on step therapy, a workable treatment was discovered for systemic sclerosis lung disease, treatment guidelines were penned for JIA-related uveitis, conflicting studies were published on treatments that may (or, may not) cause deadly infections, among others.
Rheumatoid arthritis and type 2 diabetes mellitus share many of the same characteristics. Both are powered by abnormal glucose metabolism and both are associated with insulin resistance and adverse cardiovascular disease outcomes. In this slideshow, we highlight some of the similarities.
Insulin resistance is independently associated with body mass index and synovitis in rheumatoid arthritis patients, shows new research published in Arthritis and Rheumatology.